Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ANTH's Cash to Debt is ranked higher than
81% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. ANTH: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ANTH' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 3.87 Max: No Debt
Current: No Debt
Equity to Asset 0.79
ANTH's Equity to Asset is ranked higher than
63% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ANTH: 0.79 )
Ranked among companies with meaningful Equity to Asset only.
ANTH' s Equity to Asset Range Over the Past 10 Years
Min: 0.73  Med: 0.79 Max: 0.81
Current: 0.79
0.73
0.81
F-Score: 5
Z-Score: -3.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -2774.35
ANTH's Operating margin (%) is ranked lower than
86% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. ANTH: -2774.35 )
Ranked among companies with meaningful Operating margin (%) only.
ANTH' s Operating margin (%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: -2774.35
Net-margin (%) -2788.16
ANTH's Net-margin (%) is ranked lower than
86% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. ANTH: -2788.16 )
Ranked among companies with meaningful Net-margin (%) only.
ANTH' s Net-margin (%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: -2788.16
ROE (%) -161.27
ANTH's ROE (%) is ranked lower than
89% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. ANTH: -161.27 )
Ranked among companies with meaningful ROE (%) only.
ANTH' s ROE (%) Range Over the Past 10 Years
Min: -582.71  Med: -473.78 Max: -179.7
Current: -161.27
-582.71
-179.7
ROA (%) -111.47
ANTH's ROA (%) is ranked lower than
88% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ANTH: -111.47 )
Ranked among companies with meaningful ROA (%) only.
ANTH' s ROA (%) Range Over the Past 10 Years
Min: -254.43  Med: -141.49 Max: -94.5
Current: -111.47
-254.43
-94.5
ROC (Joel Greenblatt) (%) -8155.31
ANTH's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. ANTH: -8155.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANTH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -263793.33  Med: -14312.76 Max: -2880.94
Current: -8155.31
-263793.33
-2880.94
EBITDA Growth (3Y)(%) -59.60
ANTH's EBITDA Growth (3Y)(%) is ranked lower than
95% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ANTH: -59.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANTH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -59.60 Max: -52
Current: -59.6
EPS Growth (3Y)(%) -59.50
ANTH's EPS Growth (3Y)(%) is ranked lower than
96% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ANTH: -59.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANTH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -59.50 Max: -50.7
Current: -59.5
» ANTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ANTH Guru Trades in Q4 2014

Jim Simons Sold Out
» More
Q1 2015

ANTH Guru Trades in Q1 2015

Jim Simons 18,303 sh (New)
» More
Q2 2015

ANTH Guru Trades in Q2 2015

Jim Simons Sold Out
» More
Q3 2015

ANTH Guru Trades in Q3 2015

Jim Simons 169,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ANTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.32
ANTH's P/B is ranked higher than
57% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. ANTH: 2.32 )
Ranked among companies with meaningful P/B only.
ANTH' s P/B Range Over the Past 10 Years
Min: 2.32  Med: 5.32 Max: 16.04
Current: 2.32
2.32
16.04
P/S 66.12
ANTH's P/S is ranked lower than
89% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. ANTH: 66.12 )
Ranked among companies with meaningful P/S only.
ANTH' s P/S Range Over the Past 10 Years
Min: 66.11  Med: 363.50 Max: 612
Current: 66.12
66.11
612
Current Ratio 4.70
ANTH's Current Ratio is ranked higher than
50% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. ANTH: 4.70 )
Ranked among companies with meaningful Current Ratio only.
ANTH' s Current Ratio Range Over the Past 10 Years
Min: 0.15  Med: 3.48 Max: 16.1
Current: 4.7
0.15
16.1
Quick Ratio 4.70
ANTH's Quick Ratio is ranked higher than
52% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. ANTH: 4.70 )
Ranked among companies with meaningful Quick Ratio only.
ANTH' s Quick Ratio Range Over the Past 10 Years
Min: 0.15  Med: 3.48 Max: 16.1
Current: 4.7
0.15
16.1
Days Sales Outstanding 283.18
ANTH's Days Sales Outstanding is ranked lower than
93% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. ANTH: 283.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANTH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 283.18

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.45
ANTH's Price/Net Cash is ranked higher than
77% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ANTH: 2.45 )
Ranked among companies with meaningful Price/Net Cash only.
ANTH' s Price/Net Cash Range Over the Past 10 Years
Min: 2.01  Med: 5.59 Max: 41.88
Current: 2.45
2.01
41.88
Price/Net Current Asset Value 2.36
ANTH's Price/Net Current Asset Value is ranked higher than
77% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. ANTH: 2.36 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ANTH' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.96  Med: 5.39 Max: 30.45
Current: 2.36
1.96
30.45
Price/Tangible Book 2.34
ANTH's Price/Tangible Book is ranked higher than
70% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. ANTH: 2.34 )
Ranked among companies with meaningful Price/Tangible Book only.
ANTH' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.96  Med: 4.56 Max: 14.45
Current: 2.34
1.96
14.45
Price/Median PS Value 0.18
ANTH's Price/Median PS Value is ranked higher than
93% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANTH: 0.18 )
Ranked among companies with meaningful Price/Median PS Value only.
ANTH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.41  Med: 1.16 Max: 1.2
Current: 0.18
0.41
1.2
Earnings Yield (Greenblatt) (%) -69.24
ANTH's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ANTH: -69.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANTH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -112.9  Med: 0.00 Max: 0
Current: -69.24
-112.9
0

More Statistics

Revenue(Mil) $1
EPS $ -1.15
Beta2.81
Short Percentage of Float9.31%
52-Week Range $2.45 - 11.65
Shares Outstanding(Mil)39.88

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:6TA1.Germany,
Anthera Pharmaceuticals Inc was incorporated on September 9, 2004 in the state of Delaware. It is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflammation and autoimmune diseases. The Company's product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages as well as plasma cells. Its product development program is focused on development of blisibimod for use as a therapeutic treatment for lupus and other serious autoimmune diseases for which it believes current treatments are either inadequate or non-existent. It currently relies on contract manufacturers to produce drug substances and drug products required for its clinical studies under current Good Manufacturing Practice with oversight by its internal managers. The Company competes with pharmaceutical and more established biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.
» More Articles for NAS:ANTH

Headlines

Articles On GuruFocus.com
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 12 2010 
Weekly CFO Buys Highlight: Inuvo Inc., Heelys Inc., Peregrine Pharmaceuticals Inc., Anthera Pharmace Sep 26 2010 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 12 2010 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
Aetna Has ‘Serious Concerns’ With ObamaCare Exchanges Feb 01 2016
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 29 2016
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 08 2016
Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President and Chief Operating... Jan 05 2016
Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President and Chief Operating... Jan 05 2016
3 Biotech Stocks Under $10 Making Big Moves Dec 30 2015
ANTHERA PHARMACEUTICALS INC Financials Dec 08 2015
Are Investors Right to Avoid Baozun Inc (ADR) (BZUN)? Nov 30 2015
ANTHERA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 09 2015
Anthera Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results Nov 06 2015
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 06 2015
Anthera reports 3Q loss Nov 06 2015
Anthera reports 3Q loss Nov 06 2015
Anthera Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results Nov 06 2015
Anthera Pharmaceuticals Announces Presentation at Healthcare Conferences, ACR Reception and Timing... Oct 28 2015
This Could Be the Next Billion Dollar Biotech Oct 11 2015
Spark Therapeutics (ONCE) Slumps: Falls 11.1% in Session Oct 08 2015
New Strong Buy Stocks for October 6th Oct 06 2015
This Company Could Be the Next CETX or CANF Oct 05 2015
Anthera Announces Initiation of the SOLUTION Clinical Study of Oral Sollpura(R) (liprotamase)... Oct 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK